MDGI Antibody (67D3): sc-58275

MDGI Antibody (67D3) is a mouse monoclonal IgG1 antibody that detects MDGI in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Mammary-derived growth inhibitor (MDGI), also known as Fatty Acid-Binding Protein 3 (FABP3), plays a crucial role in the transport and metabolism of fatty acids, which are essential for energy production and cellular function. MDGI is predominantly expressed in the myocardium and muscle tissues, where MDGI facilitates the uptake and intracellular transport of fatty acids, thereby influencing lipid metabolism and energy homeostasis. MDGI′s ability to bind and transport fatty acids is vital for maintaining the balance between lipid and carbohydrate metabolism, particularly in tissues with high energy demands such as the heart and skeletal muscles. Additionally, MDGI has been implicated in various physiological processes, including cell signaling and the regulation of gene expression, making MDGI an important target for research in metabolic disorders and cardiovascular diseases. Anti-MDGI antibody (67D3) is an invaluable tool for researchers investigating the intricate roles of fatty acid-binding proteins in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MDGI Antibody (67D3) References:

1. Breast cancer growth inhibition by delivery of the MDGI-derived peptide P108.  |  Wang, HL. and Kurtz, A. 2000. Oncogene. 19: 2455-60. PMID: 10828888
2. Deletion of the gene encoding H-FABP/MDGI has no overt effects in the mammary gland.  |  Clark, AJ., et al. 2000. Transgenic Res. 9: 439-44. PMID: 11206972
3. Mammary-derived growth inhibitor (MDGI) cloned from human breast epithelial cells is expressed in fully differentiated lobular structures.  |  Hu, Y., et al. 1997. Int J Oncol. 11: 5-11. PMID: 21528173
4. Preservation of cochlear function in Fabp3 (H-Fabp) knockout mice.  |  Suzuki, J., et al. 2014. Neurosci Res. 81-82: 64-8. PMID: 24560810
5. Overexpression of FABP3 inhibits human bone marrow derived mesenchymal stem cell proliferation but enhances their survival in hypoxia.  |  Wang, S., et al. 2014. Exp Cell Res. 323: 56-65. PMID: 24583397
6. Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC).  |  Tang, Z., et al. 2016. Oncotarget. 7: 46253-46262. PMID: 27323829
7. Concentration-Dependent Type 1 Interferon-Induced Regulation of MX1 and FABP3 in Bovine Endometrial Explants.  |  Schabmeyer, ST., et al. 2021. Animals (Basel). 11: PMID: 33494350
8. Fatty Acid Binding Protein 3 (FABP3) and Apolipoprotein E4 (ApoE4) as Lipid Metabolism-Related Biomarkers of Alzheimer's Disease.  |  Dulewicz, M., et al. 2021. J Clin Med. 10: PMID: 34300173
9. FABP3 Deficiency Exacerbates Metabolic Derangement in Cardiac Hypertrophy and Heart Failure via PPARα Pathway.  |  Zhuang, L., et al. 2021. Front Cardiovasc Med. 8: 722908. PMID: 34458345
10. Silencing the FABP3 gene in insulin-secreting cells reduces fatty acid uptake and protects against lipotoxicity.  |  Hyder, A., et al. 2024. Acta Diabetol. 61: 1577-1588. PMID: 38960943

The preferred B-FABP antibody is B-FABP Antibody (F-6): sc-374588.